Group 1 - The core viewpoint of the news is that Jiuzhoutong has successfully established itself as a leader in the pharmaceutical logistics sector by launching the first public REITs and Pre-REITs fund in China, enhancing its asset management capabilities and market value [1][2] - Jiuzhoutong's 2024 revenue reached 151.81 billion yuan, with a net profit attributable to shareholders of 2.507 billion yuan, reflecting a year-on-year revenue growth of 2.58% and a net profit growth of 39.88% after adjusting for seasonal factors [2] - In Q1 2025, Jiuzhoutong reported a revenue of 42.016 billion yuan, a 3.82% increase year-on-year, and a net profit of approximately 970 million yuan, marking an 80.38% increase compared to the same period last year [2] Group 2 - The issuance of public REITs is a significant part of Jiuzhoutong's strategic transformation, aimed at revitalizing its pharmaceutical logistics assets and facilitating rapid business growth [1] - Jiuzhoutong has become the first company in the pharmaceutical industry to establish a dual listing platform of "equity + assets," setting a benchmark for asset management in the pharmaceutical distribution sector [1]

Group 1 - The core viewpoint of the news is that Jiuzhoutong is successfully implementing its new retail strategy, which focuses on a comprehensive online and offline service system aimed at end consumers [1] - As of now, Jiuzhoutong has nearly 30,000 franchise pharmacies, with new retail revenue expected to reach nearly 3 billion yuan in 2024 [1] - The company reported a rapid growth in sales revenue from franchise pharmacies, reaching 5.392 billion yuan in 2024, a year-on-year increase of 54.94% [1] Group 2 - In 2024, Jiuzhoutong achieved a revenue of 151.81 billion yuan and a net profit attributable to shareholders of 2.507 billion yuan, with a year-on-year revenue growth of 2.58% after excluding seasonal disease impacts [2] - The first quarter of 2025 saw Jiuzhoutong generate a revenue of 42.016 billion yuan, a 3.82% increase compared to the same period last year, with a net profit of approximately 970 million yuan, reflecting an 80.38% year-on-year growth [2] - The company’s non-recurring net profit for 2024 was 1.814 billion yuan, showing a year-on-year increase of 14.89% [2]

Group 1 - The 2024 annual performance briefing for the Shanghai Stock Exchange main board was held, focusing on the company's operational situation, strategic transformation, and future development plans [1] - The company achieved a sales revenue of 3.007 billion yuan in 2024, representing a year-on-year growth of 21.49%, driven by the expansion of its pharmaceutical manufacturing and OEM business [2] - The pharmaceutical segment, particularly the Western medicine sector, saw a revenue increase of 26.92% in 2024, reaching 592 million yuan, with a diverse product range including over 150 products [2][3] Group 2 - The company reported a total revenue of 151.81 billion yuan for 2024, with a net profit attributable to shareholders of 2.507 billion yuan, reflecting a year-on-year net profit growth of 39.88% [4] - In Q1 2025, the company achieved a revenue of 42.016 billion yuan, a 3.82% increase from the previous year, and a net profit of approximately 970 million yuan, marking an 80.38% year-on-year growth [4]

Group 1 - The core viewpoint of the news is that Jiuzhoutong is focusing on its new product strategy and has shown significant growth in revenue and profit in 2024, with a strong emphasis on brand promotion and marketing capabilities [1][2] - In 2024, Jiuzhoutong's total sales revenue from its general agency brand promotion business (including pharmaceuticals and medical devices) reached 19.267 billion yuan, with a gross profit of 2.16 billion yuan [1] - The company has introduced a total of 2,247 specifications of pharmaceuticals and medical devices, with 52 single products achieving sales exceeding 100 million yuan [1] Group 2 - Jiuzhoutong reported a revenue of 151.81 billion yuan and a net profit attributable to shareholders of 2.507 billion yuan for the year 2024, with a year-on-year revenue growth of 2.58% and a net profit growth of 39.88% [2] - In the first quarter of 2025, the company achieved a revenue of 42.016 billion yuan, representing a year-on-year growth of 3.82%, and a net profit of approximately 970 million yuan, which is an increase of 80.38% compared to the same period last year [2]

Core Viewpoint - The company, Jiuzhoutong, showcased its strategic transformation and growth in the traditional Chinese medicine sector during the 2024 annual performance briefing, highlighting significant revenue growth and a comprehensive industry chain approach [1][2]. Company Performance - In 2024, Jiuzhoutong achieved a total revenue of 151.81 billion yuan, with a net profit attributable to shareholders of 2.507 billion yuan, reflecting a year-on-year increase of 39.88% [3]. - The company reported a net profit of 1.814 billion yuan after excluding non-recurring items, marking a year-on-year growth of 14.89% [3]. - For Q1 2025, Jiuzhoutong's revenue reached 42.016 billion yuan, a 3.82% increase compared to the same period last year, with a net profit of approximately 970 million yuan, representing an 80.38% year-on-year growth [3]. Traditional Chinese Medicine Business Development - The traditional Chinese medicine segment generated sales revenue of 4.962 billion yuan in 2024, a year-on-year increase of 18.14%, with a gross profit of 871 million yuan, up 12.22% [1][2]. - The company has established a full industry chain layout in traditional Chinese medicine, focusing on "authentic medicinal materials + intelligent manufacturing + digital services" [1]. Resource Management and Quality Control - Jiuxin Traditional Chinese Medicine has set up nine core authentic medicinal material production areas across the country and invested in 21 specialized companies, managing 250,000 acres of standardized planting bases [2]. - The company has achieved GAP certification for 14 medicinal material bases and has developed a traceability platform for traditional Chinese medicine quality in Hubei Province [2]. Production and R&D Capabilities - Jiuxin Traditional Chinese Medicine has built 13 GMP-certified modern processing enterprises and has established a smart traditional Chinese medicine service with over 6,000 professional decoction devices [2]. - The company has a core R&D team of over 70 members, involved in more than 30 national and provincial key projects, and has formed a patent cluster covering over 200 items [2]. Marketing and Digitalization - The company has expanded its marketing efforts into four major areas: OTC, medical, medicinal materials, and online business, serving over 100,000 downstream clients [2]. - Jiuzhoutong has developed digital systems for quality traceability, smart decoction, and traditional Chinese medicine diagnosis, enhancing the digital management and service capabilities of its traditional Chinese medicine business [3].

此外，公司积极拥抱AI人工智能技术，通过自主研发与外部合作双轮驱动，开发针对不同应用场景的 AI智能体，加速业务及管理的数智化转型。在AI及大模型领域，公司与阿里云、腾讯云等头部科技企 业进行合作，分别在公司智慧知识管理、通义灵码、诊疗系统的处方辅助诊断和 AI 健康教育处方等方 面开展应用合作。 4月28日晚，九州通发布2024年年报及2025年第一季度报告，公司业绩"稳"中有"进"，2024年营收达 1,518.10亿元，归母净利润25.07亿元，扣非归母净利润18.14亿元。如剔除上年季节性疾病等特定因素影 响，公司2024年营收同比增长2.58%，归母净利润同比增长39.88%，扣非归母净利润同比增长14.89%。 5月7日下午，2024年度沪市主板集体业绩说明会新质生产力之民营活力专场活动召开，九州通 （600998）董事长刘长云、副总经理全铭出席了本次活动，并围绕公司2024年经营情况、"三新两化"战 略转型成效及未来发展规划等问题与投资者进行了充分交流。 有投资者提问称，今年以来，大数据、AI的快速发展推动各行各业不断蜕变转型，公司也把数字化作 为核心战略之一，想请教一下目前数字化及AI对公司业 ...

Group 1 - The company plans to distribute a cash dividend of 2.00 yuan per 10 shares for the year 2024, totaling 999.7 million yuan, which represents 50.47% of the annual net profit attributable to shareholders [1] - The cumulative cash dividends and stock buybacks since the company's listing have reached 6.861 billion yuan, which is 125% of the refinancing balance, excluding the controlling shareholder's subscription amount [1] - The company has established a "Future Three-Year Dividend Return Plan (2025-2027)" to outline its cash dividend policies for the next three years, reflecting its commitment to investor returns and confidence in future development [1] Group 2 - In 2024, the company achieved a revenue of 151.81 billion yuan and a net profit attributable to shareholders of 2.507 billion yuan, with a year-on-year revenue growth of 2.58% and a net profit growth of 39.88% after excluding specific seasonal factors [2] - For the first quarter of 2025, the company reported a revenue of 42.016 billion yuan, a year-on-year increase of 3.82%, and a net profit of approximately 970 million yuan, reflecting a significant growth of 80.38% compared to the same period last year [2]

基于 2024 年度现场检查，本保荐人提请贵公司关注以下事项：建议公司继 续严格按照《公司法》《证券法》《上海证券交易所股票上市规则》等法律法规的 要求，不断完善公司治理结构，及时履行信息披露义务。 附件：《中信证券股份有限公司关于九州通医药集团股份有限公司 2024 年度 持续督导工作现场检查报告》 1 （本页无正文，为《中信证券股份有限公司关于九州通医药集团股份有限公 司 2024 年持续督导工作现场检查结果及提请公司注意事项》之盖章页） 中信证券股份有限公司 关于九州通医药集团股份有限公司 2024 年持续督导工作现场检 查结果及提请公司注意事项 九州通医药集团股份有限公司： 中信证券股份有限公司（以下简称"本保荐人"）作为对贵公司进行持续督 导的保荐人，按照《上海证券交易所上市公司自律监管指引第 11 号——持续督 导》的有关要求，对贵公司认真履行了持续督导职责。 保荐人：中信证券股份有限公司 年 月 日 ...

中信证券股份有限公司 关于九州通医药集团股份有限公司 2024年度持续督导报告书 | 上市公司：九州通医药集团股份有限公司（以下简称"九州通"、"公司"） | | | --- | --- | | 保荐人名称：中信证券股份有限公司（以下简称"中信证券"或"保荐人"） | | | 保荐代表人姓名：王国梁 5210 | 联系电话：0755-2383 | | 保荐代表人姓名：叶兴林 5003 | 联系电话：0755-2383 | 经中国证券监督管理委员会《关于同意九州通医药集团股份有限公司向特定 对象发行优先股注册的批复》（证监许可［2024］1002 号）核准，并经上海证 券交易所同意，公司于 2024 年 8 月 12 日向特定对象发行优先股 1,790 万股，发 行价格为每股 100 元，募集资金总额为 1,790,000,000.00 元，扣除各类发行费用 之后实际募集资金净额 1,771,903,773.59 元。中审众环会计师事务所（特殊普通 合伙）于 2024 年 8 月 13 日对九州通医药集团股份有限公司向特定对象发行优先 股的资金到位情况进行了审验，并出具了"众环验字（2024）0100025 号 ...

中信证券股份有限公司 关于九州通医药集团股份有限公司 （四）现场检查时间 2024 年度持续督导工作现场检查报告 根据《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有 关法律、法规的规定，中信证券股份有限公司（以下简称"中信证券"或"保荐 人"）作为正在对九州通医药集团股份有限公司（以下简称"九州通""公司" "上市公司"）进行持续督导工作的保荐人，对自 2024 年发行上市之日至 2024 年 12 月 31 日（以下简称"本持续督导期间"）的规范运作情况进行了现场检查， 现就现场检查的有关情况报告如下： 一、本次现场检查的基本情况 （一）保荐人 中信证券股份有限公司 （二）保荐代表人 王国梁、叶兴林 （三）现场检查人员 王国梁 2025 年 4 月 26 日 （五）现场检查内容 现场检查人员对本持续督导期内发行人公司治理和内部控制情况、信息披露 情况、公司的独立性以及与控股股东、实际控制人及其他关联方资金往来情况、 募集资金使用情况、关联交易、对外担保、重大对外投资情况、经营状况等方面 进行了现场检查，具体检查内容详见本报告"二、本次现场检查主要事项及意见"。 1 （六）现场检查手段 本 ...